PR Newswire Clinical TrialsOriginal article
SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
ConferenceSKYRIZIRINVOQPositive
AI Analysis
Summary
AbbVie announced 20 scientific presentations at UEGW 2026 highlighting long-term and real-world clinical and endoscopic outcomes for SKYRIZI (risankizumab) and RINVOQ (upadacitinib) across inflammatory bowel disease.
Outcome Details
20 scientific presentations at UEGW 2026 featuring long-term and real-world clinical and endoscopic outcomes data for SKYRIZI and RINVOQ in IBD.
Importance:5/10
Sentiment:
0.40
UEGW 2026IBDCrohn's diseaseulcerative colitislong-term datareal-world dataendoscopic outcomesconference presentation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on October 17, 2026 6:00 AM